Testing the addition of the immunotherapy drug pembrolizumab to chemotherapy treatment in stage III-IV or recurrent endometrial cancer (H-46501)
Description
Content
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent).
Contact
Phone 1: 713–798–1354
IRB: H-46501
Status:
Active
Created:
